Cellectis amends 6-K to add iXBRL; no changes to results

Rhea-AI Filing Summary

Cellectis S.A. filed an amended Form 6-K/A to update its prior submission solely to provide the company’s unaudited interim financial statements in iXBRL format. The amendment covers the three- and six-month periods ended June 30, 2025 and is made in accordance with Rule 405 of Regulation S‑T and the Form 6‑K instructions.

The company states the amendment does not amend, revise, update, or restate other information in the original report. The materials are deemed incorporated by reference into Cellectis’s registration statements on Form F‑3 (Nos. 333‑284302, 333‑288491) and Form S‑8 (including Nos. 333‑204205, 333‑214884, 333‑222482, 333‑227717, 333‑258514, 333‑267760, 333‑273777, 333‑284301).

Q2--12-310001627281trueJune 30, 2025 0001627281clls:TrancheAWarrantsMemberclls:EuropeanInvestmentBankLoanMember2023-04-170001627281clls:CurrentLeaseDebtsMember2024-12-310001627281ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember2024-12-310001627281clls:NonEmployeeWarrantsMember2023-12-310001627281clls:LicenseAgreementWithServierMember2024-04-012024-06-300001627281ifrs-full:TopOfRangeMember2025-01-012025-06-300001627281clls:SellingGeneralAndAdministrativeExpenses1Member2025-04-012025-06-300001627281clls:NonCurrentDerivativeInstrumentsMemberifrs-full:Level2OfFairValueHierarchyMember2024-12-310001627281clls:OtherCurrentLiabilities1Member2025-06-300001627281clls:ClinicalAndRdAgreementsMemberifrs-full:NotLaterThanOneYearMember2025-06-300001627281clls:JointCollaborationAndResearchAgreementMember2023-11-012023-11-010001627281clls:EuropeanInvestmentBankLoanMember2022-12-280001627281clls:ClassAConvertiblePreferredSharesMember2024-05-030001627281clls:BpifranceMemberclls:ResearchTaxCreditFinancingsMember2022-06-152022-06-150001627281clls:FixturesFittingsAndOtherEquipmentMember2024-06-300001627281clls:IncomeLossMember2024-12-310001627281clls:FixturesFittingsAndOtherEquipmentMember2025-06-300001627281clls:StateGuaranteedLoanMember2025-01-012025-06-300001627281ifrs-full:TradeReceivablesMemberifrs-full:Level3OfFairValueHierarchyMember2024-12-310001627281clls:CurrentFinancialLiabilitiesMemberifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember2024-12-310001627281clls:TrancheAWarrantsMemberclls:ExpectedVolatilityPlusFivePercentMember2025-06-300001627281clls:SubsequentInvestmentAgreementMember2024-05-030001627281clls:TrancheCWarrantsMemberclls:ExpectedVolatilityLessFivePercentMember2025-06-300001627281ifrs-full:BuildingsMember2024-12-310001627281clls:StateGuarantedLoanMember2024-12-310001627281ifrs-full:LandAndBuildingsMemberifrs-full:GrossCarryingAmountMember2024-06-300001627281clls:NonEmployeeWarrantsMember2024-06-300001627281clls:CurrentFinancialAssetsMemberifrs-full:Level3OfFairValueHierarchyMember2025-06-300001627281clls:TrancheAWarrantsMember2025-06-300001627281clls:TechnicalEquipmentsMember2025-01-012025-06-300001627281clls:NonCurrentLeaseDebtsMemberifrs-full:Level2OfFairValueHierarchyMember2024-12-310001627281ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberclls:OtherCurrentLiabilities1Member2024-12-310001627281clls:FreeSharesMember2025-06-300001627281clls:AstraZenecaMember2025-06-300001627281ifrs-full:GrossCarryingAmountMemberclls:TechnicalEquipmentsMember2025-06-300001627281ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMemberclls:OtherCurrentLiabilities1Member2024-12-310001627281clls:CurrentFinancialLiabilitiesMemberifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember2025-06-300001627281ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberclls:TechnicalEquipmentsMember2024-06-300001627281clls:CurrentLeaseDebtsMemberifrs-full:Level2OfFairValueHierarchyMember2024-12-310001627281clls:CalyxtIncMember2025-01-012025-06-300001627281clls:NonCurrentDerivativeInstrumentsMember2024-12-310001627281clls:NonCurrentFinancialAssetsMemberifrs-full:Level2OfFairValueHierarchyMember2024-12-310001627281clls:NonCurrentDerivativeInstrumentsMember2025-06-300001627281ifrs-full:SellingGeneralAndAdministrativeExpenseMember2024-04-012024-06-300001627281clls:EuropeanInvestmentBankLoanMember2024-12-310001627281clls:TrancheCWarrantsMember2024-12-180001627281clls:TotalNon-CurrentFinancialLiabilitiesAndNon-CurrentLeaseDebtsMember2024-12-310001627281clls:AstraZenecaMemberclls:JointCollaborationAndResearchAgreementMember2023-11-012023-11-010001627281clls:EuropeanInvestmentBankWarrantsMember2024-12-310001627281ifrs-full:OrdinarySharesMember2025-06-300001627281clls:LeasedEquipmentMember2025-01-012025-06-300001627281clls:TradePayablesMember2025-06-300001627281clls:AstraZenecaIrelandMemberclls:JointCollaborationAndResearchAgreementMember2024-04-012024-06-3000016272812021-01-012021-12-310001627281clls:NonCurrentDerivativeInstrumentsMemberifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember2025-06-300001627281ifrs-full:TradeReceivablesMemberifrs-full:FinancialAssetsAtAmortisedCostCategoryMember2025-06-300001627281clls:EuropeanInvestmentBankLoanMember2025-01-012025-06-300001627281ifrs-full:Level3OfFairValueHierarchyMember2024-12-310001627281ifrs-full:Level2OfFairValueHierarchyMember2024-12-310001627281ifrs-full:BuildingsMemberifrs-full:GrossCarryingAmountMember2025-06-300001627281clls:InitialInvestmentAgreementMember2023-11-010001627281clls:FreeSharesMember2023-12-310001627281ifrs-full:SharePremiumMember2025-01-012025-06-300001627281clls:Non-CurrentLeaseLiabilitiesMember2025-06-300001627281clls:CurrentPortionOfState-GuaranteedLoanMember2025-06-300001627281ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberclls:OfficeAndLaboratoryEquipmentMember2025-06-300001627281ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberclls:OtherNonCurrentFinancialLiabilitiesMember2025-06-300001627281clls:TrancheBWarrantsMember2024-12-310001627281ifrs-full:Level2OfFairValueHierarchyMemberclls:OtherNonCurrentFinancialLiabilitiesMember2024-12-310001627281ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberclls:TradePayablesMember2024-12-310001627281clls:EmployeeLitigationAndSeveranceMember2025-06-300001627281clls:AstraZenecaMemberifrs-full:TopOfRangeMemberclls:JointCollaborationAndResearchAgreementMember2023-11-012023-11-010001627281ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMemberclls:OtherNonCurrentFinancialLiabilitiesMember2024-12-310001627281clls:CellectisIncMember2025-01-012025-06-300001627281ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2024-06-300001627281clls:EmployeeLitigationAndSeveranceMember2025-01-012025-06-300001627281clls:ResearchTaxCreditFinancingsMember2025-06-300001627281clls:CarryingAmountAndValueMember2024-12-310001627281clls:CurrentFinancialAssetsMember2024-12-310001627281ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:ConstructionInProgressMember2024-06-300001627281ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember2024-12-310001627281ifrs-full:GrossCarryingAmountMemberifrs-full:ConstructionInProgressMember2025-06-300001627281clls:EuropeanInvestmentBankLoanMember2025-06-300001627281clls:EuropeanInvestmentBankLoanTrancheCMember2024-12-182024-12-180001627281clls:BPIRefundableAdvanceAgreementMember2025-01-012025-06-300001627281clls:CurrentFinancialLiabilitiesMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember2024-12-310001627281ifrs-full:IssuedCapitalMemberifrs-full:OrdinarySharesMember2025-01-012025-06-300001627281ifrs-full:BottomOfRangeMemberclls:StockOption1Member2025-01-012025-06-300001627281clls:LeasedPremisesMemberstpr:NY2025-06-300001627281clls:InitialInvestmentAgreementMember2023-11-012023-11-010001627281clls:FixturesFittingsAndOtherEquipmentMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2024-06-300001627281clls:NonCurrentLeaseDebtsMemberifrs-full:Level1OfFairValueHierarchyMember2024-12-310001627281clls:AstraZenecaIrelandMemberclls:JointCollaborationAndResearchAgreementMember2025-04-012025-06-300001627281clls:CashAndCashEquivalentMemberifrs-full:Level1OfFairValueHierarchyMember2025-06-300001627281clls:CurrentFinancialAssetsMemberifrs-full:Level1OfFairValueHierarchyMember2024-12-310001627281clls:ITLicensingAgreementMemberifrs-full:LaterThanFiveYearsMember2025-06-300001627281ifrs-full:ConstructionInProgressMember2024-12-310001627281clls:OtherCurrentFinancialLiabilitiesMember2025-01-012025-06-300001627281clls:StockOption1Member2023-12-310001627281clls:CurrentLeaseLiabilitiesMember2024-12-310001627281clls:AstraZenecaMember2025-06-300001627281clls:IncomeLossMember2024-01-012024-06-300001627281clls:AdditionalResearchPlansUnderTheAZJRCAOneMember2024-09-130001627281ifrs-full:PreferenceSharesMember2024-01-012024-06-300001627281ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2025-06-300001627281clls:ITLicensingAgreementMember2025-06-300001627281ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberclls:NonCurrentDerivativeInstrumentsMember2024-12-310001627281clls:OtherProvisionForChargesMember2025-06-300001627281clls:OtherNonCurrentFinancialLiabilitiesMember2025-06-300001627281clls:CurrentFinancialAssetsMemberifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember2025-06-300001627281ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember2024-12-310001627281clls:BPIRefundableAdvanceAgreementMember2025-06-300001627281clls:NonCurrentFinancialAssetsMemberifrs-full:Level3OfFairValueHierarchyMember2024-12-310001627281ifrs-full:TopOfRangeMemberclls:JointCollaborationAndResearchAgreementMember2023-11-010001627281clls:StockOption1Member2023-01-012023-12-310001627281clls:CurrentFinancialLiabilitiesMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember2025-06-300001627281ifrs-full:BottomOfRangeMember2024-01-012024-06-300001627281clls:NonEmployeeWarrantsMember2024-12-310001627281clls:AstraZenecaMember2023-11-062023-11-060001627281ifrs-full:BottomOfRangeMemberclls:StockOption1Member2024-01-012024-06-300001627281clls:SubsidiesReceivablesMember2025-06-300001627281clls:StockOption1Member2025-06-232025-06-230001627281ifrs-full:SellingGeneralAndAdministrativeExpenseMember2024-01-012024-06-300001627281ifrs-full:GrossCarryingAmountMemberclls:OfficeAndLaboratoryEquipmentMember2025-06-300001627281clls:OtherCurrentLiabilities1Memberifrs-full:Level3OfFairValueHierarchyMember2024-12-310001627281clls:IncomeLossMember2023-12-310001627281clls:EuropeanInvestmentBankLoanTrancheCMember2024-12-180001627281ifrs-full:LaterThanFiveYearsMember2024-12-310001627281clls:SubsequentInvestmentAgreementMember2023-11-140001627281clls:IncomeLossMember2024-06-300001627281clls:CurrentLeaseDebtsMemberifrs-full:Level1OfFairValueHierarchyMember2024-12-310001627281clls:ExecutiveEmployeesMemberclls:StockOption1Member2025-06-232025-06-230001627281clls:FixturesFittingsAndOtherEquipmentMemberifrs-full:GrossCarryingAmountMember2024-06-300001627281ifrs-full:IssuedCapitalMember2025-06-300001627281clls:TechnicalEquipmentsMember2025-06-300001627281clls:NonCurrentDerivativeInstrumentsMemberifrs-full:Level3OfFairValueHierarchyMember2024-12-310001627281ifrs-full:TradeReceivablesMemberifrs-full:Level2OfFairValueHierarchyMember2024-12-310001627281clls:OtherNonCurrentFinancialLiabilitiesMemberifrs-full:Level1OfFairValueHierarchyMember2024-12-310001627281clls:CurrentFinancialLiabilitiesMember2025-06-300001627281ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember2025-06-300001627281clls:CurrentFinancialAssetsMemberifrs-full:FinancialAssetsAtAmortisedCostCategoryMember2025-06-300001627281clls:SellingGeneralAndAdministrativeExpenses1Member2024-04-012024-06-300001627281clls:FixturesFittingsAndOtherEquipmentMember2024-01-012024-06-300001627281clls:ExpectedVolatilityLessFivePercentMemberclls:TrancheBWarrantsMember2025-06-300001627281ifrs-full:PreferenceSharesMember2024-06-300001627281clls:CommercialLitigationMember2025-01-012025-06-300001627281clls:BPIRefundableAdvanceAgreementMemberifrs-full:InterestRateMeasurementInputMember2023-10-060001627281clls:CurrentLeaseDebtsMemberifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember2024-12-310001627281ifrs-full:TradeReceivablesMemberifrs-full:Level1OfFairValueHierarchyMember2024-12-310001627281clls:ProvisionForTaxLitigationMember2025-01-012025-06-300001627281clls:StateGuaranteedLoanMemberifrs-full:BottomOfRangeMember2025-06-300001627281clls:BPIRefundableAdvanceAgreementMember2023-10-062023-10-060001627281clls:StockOption1Member2024-12-310001627281country:FR2025-01-012025-06-300001627281ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberclls:TradePayablesMember2025-06-300001627281clls:OtherNonCurrentFinancialLiabilitiesMember2024-12-310001627281clls:NonCurrentFinancialAssetsMemberifrs-full:Level1OfFairValueHierarchyMember2025-06-300001627281clls:ClinicalAndRdAgreementsMemberifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember2024-12-310001627281clls:EuropeanInvestmentBankWarrantsMember2025-06-300001627281ifrs-full:OrdinarySharesMember2024-01-012024-06-300001627281clls:CashAndCashEquivalentMemberifrs-full:FinancialAssetsAtAmortisedCostCategoryMember2025-06-300001627281clls:CurrentLeaseDebtsMemberifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember2025-06-300001627281ifrs-full:BottomOfRangeMemberclls:JointCollaborationAndResearchAgreementMember2023-11-010001627281clls:CellectisBiologicsIncMemberclls:CellectisIncMember2025-01-012025-06-300001627281clls:JointCollaborationAndResearchAgreementMember2023-11-142023-11-140001627281ifrs-full:RetainedEarningsMember2025-01-012025-06-300001627281ifrs-full:BuildingsMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2024-06-300001627281ifrs-full:PreferenceSharesMember2023-11-140001627281clls:EuropeanInvestmentBankWarrantsMember2025-01-012025-06-300001627281clls:CurrentFinancialLiabilitiesMember2024-12-310001627281clls:AstraZenecaMemberifrs-full:OrdinarySharesMember2023-11-060001627281ifrs-full:BuildingsMember2025-01-012025-06-300001627281clls:Non-CurrentLeaseLiabilitiesMember2024-12-310001627281clls:EuropeanInvestmentBankLoanMember2025-06-300001627281ifrs-full:GrossCarryingAmountMemberclls:TechnicalEquipmentsMember2024-06-300001627281ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMemberclls:OtherCurrentLiabilities1Member2025-06-300001627281clls:NonCurrentFinancialAssetsMemberifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember2024-12-310001627281clls:OtherNonCurrentFinancialLiabilitiesMemberifrs-full:Level3OfFairValueHierarchyMember2024-12-310001627281clls:EuropeanInvestmentBankWarrantsMember2025-01-012025-06-300001627281clls:NonCurrentLeaseDebtsMember2025-06-300001627281clls:NonCurrentLeaseDebtsMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember2025-06-300001627281ifrs-full:LandAndBuildingsMember2024-12-310001627281clls:ITLicensingAgreementMemberifrs-full:NotLaterThanOneYearMember2024-12-310001627281clls:ProvisionForTaxLitigationMember2024-12-310001627281clls:AstraZenecaMember2024-05-032024-05-030001627281ifrs-full:LandAndBuildingsMember2025-01-012025-06-300001627281clls:CurrentFinancialAssetsMember2025-06-300001627281clls:NonCurrentDerivativeInstrumentsMemberifrs-full:Level3OfFairValueHierarchyMember2025-06-300001627281clls:TrancheAWarrantsMember2024-12-310001627281ifrs-full:Level2OfFairValueHierarchyMemberclls:TradePayablesMember2024-12-310001627281clls:CashAndCashEquivalentMemberifrs-full:FinancialAssetsAtAmortisedCostCategoryMember2024-12-310001627281clls:LeasedPremisesMemberstpr:NC2025-06-300001627281clls:SubsidiesReceivablesMemberifrs-full:Level2OfFairValueHierarchyMember2024-12-310001627281clls:BPIRefundableAdvanceAgreementMemberclls:BpifranceMember2025-06-300001627281ifrs-full:IssuedCapitalMember2024-12-310001627281ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember2024-12-310001627281clls:RetirementIndemnitiesMember2025-01-012025-06-300001627281ifrs-full:LandAndBuildingsMember2024-01-012024-06-300001627281clls:FreeSharesMember2024-06-300001627281ifrs-full:BuildingsMemberifrs-full:GrossCarryingAmountMember2024-06-300001627281ifrs-full:BuildingsMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2025-06-300001627281clls:CashAndCashEquivalentMember2025-06-300001627281clls:AdditionalResearchPlansUnderTheAZJRCATwoMember2024-09-130001627281clls:LeasedEquipmentMemberstpr:NC2025-01-012025-06-300001627281ifrs-full:NotLaterThanOneYearMember2025-06-300001627281ifrs-full:RetainedEarningsMember2025-06-300001627281clls:JointCollaborationAndResearchAgreementMember2024-03-042024-03-040001627281clls:CurrentFinancialAssetsMemberifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember2024-12-310001627281clls:OtherNonCurrentFinancialLiabilitiesMember2025-01-012025-06-300001627281clls:SubsidiesReceivablesMember2024-12-310001627281clls:CurrentPortionOfState-GuaranteedLoanMember2025-01-012025-06-300001627281clls:CurrentLeaseLiabilitiesMember2025-06-300001627281ifrs-full:LandAndBuildingsMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2025-06-300001627281clls:NonCurrentFinancialAssetsMemberifrs-full:Level1OfFairValueHierarchyMember2024-12-310001627281clls:RetirementIndemnitiesMember2025-06-300001627281clls:BPIRefundableAdvanceAgreementMember2024-12-060001627281clls:ITLicensingAgreementMemberifrs-full:LaterThanFiveYearsMember2024-12-310001627281clls:AstraZenecaMember2024-12-310001627281clls:ExpectedVolatilityPlusFivePercentMemberclls:TrancheBWarrantsMember2025-06-300001627281clls:AstraZenecaMember2024-12-310001627281ifrs-full:OrdinarySharesMember2023-12-310001627281clls:TrancheCWarrantsMember2024-12-310001627281clls:CurrentPortionOfState-GuaranteedLoanMember2024-12-310001627281clls:StockOption1Member2025-01-012025-06-300001627281clls:TotalCurrentFinancialLiabilitiesAndCurrentLeaseDebtsMember2024-12-310001627281clls:CurrentLeaseLiabilitiesMember2025-01-012025-06-300001627281ifrs-full:GrossCarryingAmountMemberclls:OfficeAndLaboratoryEquipmentMember2024-06-300001627281clls:EuropeanInvestmentBankLoanTrancheBMember2024-01-250001627281ifrs-full:LandAndBuildingsMember2023-12-310001627281clls:OtherCurrentFinancialLiabilitiesMember2025-06-300001627281clls:TrancheAWarrantsMember2023-04-170001627281clls:LicenseAgreementWithServierMember2024-01-012024-06-300001627281clls:CibusSharesMember2025-01-012025-06-300001627281clls:OtherNonCurrentFinancialLiabilitiesMemberifrs-full:Level3OfFairValueHierarchyMember2025-06-300001627281clls:ResearchAndDevelopmentExpensesMember2024-01-012024-06-300001627281clls:RetirementIndemnitiesMember2024-12-310001627281ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMemberclls:OtherNonCurrentFinancialLiabilitiesMember2025-06-300001627281clls:AstraZenecaIrelandMemberclls:JointCollaborationAndResearchAgreementMember2024-01-012024-06-300001627281ifrs-full:GrossCarryingAmountMemberifrs-full:ConstructionInProgressMember2024-06-300001627281clls:TrancheCWarrantsMemberclls:EuropeanInvestmentBankLoanMember2024-12-182024-12-180001627281clls:EuropeanInvestmentBankWarrantsMember2025-06-300001627281clls:StateGuarantedLoanMember2025-06-300001627281ifrs-full:IssuedCapitalMemberifrs-full:PreferenceSharesMember2024-01-012024-06-300001627281ifrs-full:Level2OfFairValueHierarchyMember2025-06-300001627281clls:OtherNonCurrentFinancialLiabilitiesMember2024-12-310001627281clls:Non-CurrentPortionOfState-GuaranteedLoanMember2025-01-012025-06-300001627281clls:NonCurrentDerivativeInstrumentsMemberifrs-full:Level1OfFairValueHierarchyMember2024-12-310001627281clls:FixturesFittingsAndOtherEquipmentMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2025-06-300001627281clls:ClassBConvertiblePreferredSharesMember2024-05-030001627281clls:BpifranceMember2025-06-300001627281ifrs-full:TradeReceivablesMember2025-06-300001627281ifrs-full:SharePremiumMember2024-12-310001627281clls:OfficeAndLaboratoryEquipmentMember2024-06-300001627281ifrs-full:GrossCarryingAmountMember2025-06-300001627281ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberclls:CurrentLeaseDebtsMember2024-12-310001627281clls:CommercialLitigationMember2025-06-300001627281ifrs-full:OrdinarySharesMember2025-01-012025-06-300001627281clls:CalyxtIncMemberclls:VotingAgreementWithCibusMember2025-01-012025-06-300001627281clls:TrancheBWarrantsMemberclls:EuropeanInvestmentBankLoanMember2024-01-252024-01-250001627281clls:NonEmployeeWarrantsMember2024-01-012024-12-310001627281ifrs-full:BuildingsMember2025-06-300001627281clls:TechnicalEquipmentsMember2023-12-310001627281clls:TechnicalEquipmentsMember2024-01-012024-06-3000016272812022-01-012022-12-310001627281clls:ITLicensingAgreementMemberifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember2024-12-310001627281clls:NonCurrentFinancialAssetsMemberifrs-full:FinancialAssetsAtAmortisedCostCategoryMember2024-12-310001627281clls:CurrentLeaseDebtsMember2025-06-300001627281ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMemberclls:TradePayablesMember2025-06-300001627281clls:ProvisionForTaxLitigationMember2025-06-300001627281clls:PrimeraTherapeuticsIncMember2025-01-012025-06-300001627281clls:SubsequentInvestmentAgreementMember2023-12-310001627281ifrs-full:SharePremiumMember2025-06-300001627281clls:BpifranceMember2025-01-012025-06-300001627281clls:CommercialLitigationMember2024-12-310001627281clls:CarryingAmountAndValueMember2025-06-300001627281ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember2025-06-300001627281ifrs-full:SharePremiumMember2024-01-012024-06-300001627281ifrs-full:Level1OfFairValueHierarchyMember2025-06-300001627281clls:NonCurrentFinancialAssetsMember2025-06-300001627281clls:TradePayablesMember2024-12-310001627281ifrs-full:SharePremiumMemberclls:SubsequentInvestmentAgreementMember2024-01-012024-06-300001627281ifrs-full:IssuedCapitalMember2023-12-310001627281clls:StockOption1Member2025-03-132025-03-130001627281clls:TrancheBWarrantsMember2024-01-252024-01-250001627281clls:FreeSharesMember2025-01-012025-06-300001627281country:FR2024-01-012024-06-300001627281ifrs-full:Level1OfFairValueHierarchyMemberclls:TradePayablesMember2024-12-310001627281ifrs-full:RetainedEarningsMember2024-01-012024-06-3000016272812023-12-310001627281ifrs-full:ConstructionInProgressMember2025-06-300001627281clls:AstraZenecaMember2023-11-060001627281clls:BpifranceMemberclls:ResearchTaxCreditFinancingsMember2025-01-012025-06-300001627281clls:BPIRefundableAdvanceAgreementMember2024-12-062024-12-060001627281clls:TotalCurrentFinancialLiabilitiesAndCurrentLeaseDebtsMember2025-01-012025-06-300001627281ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2025-01-012025-06-300001627281clls:BPIRefundableAdvanceAgreementMemberifrs-full:InterestRateMeasurementInputMember2024-12-060001627281clls:BPIRefundableAdvanceAgreementMember2025-06-300001627281ifrs-full:PreferenceSharesMember2025-06-300001627281ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberclls:NonCurrentDerivativeInstrumentsMember2025-06-300001627281clls:TotalNon-CurrentFinancialLiabilitiesAndNon-CurrentLeaseDebtsMember2025-06-300001627281clls:BPIRefundableAdvanceAgreementMember2023-06-192023-06-190001627281ifrs-full:RetainedEarningsMember2024-12-310001627281ifrs-full:OrdinarySharesMember2024-12-310001627281clls:StateGuaranteedLoanMemberclls:BpifranceMember2025-01-012025-06-300001627281clls:EmployeeLitigationAndSeveranceMember2024-12-310001627281ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMemberclls:TradePayablesMember2024-12-310001627281clls:OfficeAndLaboratoryEquipmentMember2025-06-300001627281clls:StockOption1Member2024-06-300001627281clls:TrancheCWarrantsMember2024-12-182024-12-180001627281ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberclls:OtherNonCurrentFinancialLiabilitiesMember2024-12-310001627281clls:ResearchAndDevelopmentExpensesMember2024-04-012024-06-300001627281clls:SubsidiesReceivablesMemberifrs-full:FinancialAssetsAtAmortisedCostCategoryMember2025-06-300001627281clls:OfficeAndLaboratoryEquipmentMember2023-12-310001627281clls:OfficeAndLaboratoryEquipmentMember2024-01-012024-06-300001627281ifrs-full:EquityInvestmentsMember2024-12-310001627281ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember2024-12-310001627281clls:CurrentFinancialLiabilitiesMemberifrs-full:Level1OfFairValueHierarchyMember2024-12-310001627281clls:CurrentFinancialLiabilitiesMemberifrs-full:Level3OfFairValueHierarchyMember2024-12-310001627281clls:ClinicalAndRdAgreementsMemberifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember2025-06-300001627281clls:NonCurrentLeaseDebtsMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember2024-12-310001627281clls:TrancheBWarrantsMember2024-01-250001627281clls:JointResearchAndCollaborationAgreementInitialInvestmentAgreementSubsequentInvestmentAgreementMember2023-11-140001627281ifrs-full:TradeReceivablesMemberifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember2024-12-310001627281ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember2025-06-300001627281clls:NonEmployeeWarrantsMember2025-06-300001627281clls:FreeSharesMember2024-01-012024-06-300001627281clls:CurrentLeaseDebtsMemberifrs-full:Level3OfFairValueHierarchyMember2024-12-310001627281ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2024-12-310001627281clls:SubsidiesReceivablesMemberifrs-full:Level1OfFairValueHierarchyMember2024-12-310001627281ifrs-full:AccumulatedImpairmentMember2024-12-310001627281clls:EuropeanInvestmentBankWarrantsMember2024-01-012024-06-300001627281ifrs-full:GrossCarryingAmountMember2024-06-300001627281clls:TechnicalEquipmentsMember2024-06-300001627281clls:SubsidiesReceivablesMemberifrs-full:Level3OfFairValueHierarchyMember2024-12-310001627281ifrs-full:SellingGeneralAndAdministrativeExpenseMember2025-01-012025-06-300001627281clls:NonCurrentFinancialAssetsMember2024-12-310001627281clls:StateGuaranteedLoanMember2025-06-300001627281clls:ResearchTaxCreditFinancingsMember2024-12-310001627281ifrs-full:SharePremiumMember2024-06-300001627281clls:BPIRefundableAdvanceAgreementMember2024-12-310001627281clls:TrancheAWarrantsMemberclls:ExpectedVolatilityLessFivePercentMember2025-06-300001627281clls:SubsequentInvestmentAgreementMember2024-01-012024-05-030001627281ifrs-full:PreferenceSharesMember2023-11-142023-11-140001627281clls:NonCurrentLeaseDebtsMemberifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember2024-12-310001627281clls:CashAndCashEquivalentMember2024-12-310001627281ifrs-full:LandAndBuildingsMember2024-06-300001627281ifrs-full:SellingGeneralAndAdministrativeExpenseMember2025-04-012025-06-300001627281clls:TrancheCWarrantsMember2025-06-300001627281clls:CurrentFinancialAssetsMemberifrs-full:Level3OfFairValueHierarchyMember2024-12-310001627281ifrs-full:PreferenceSharesMember2024-12-310001627281ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2024-06-300001627281clls:ITLicensingAgreementMember2024-12-310001627281clls:JointCollaborationAndResearchAgreementMember2024-12-012024-12-310001627281ifrs-full:Level2OfFairValueHierarchyMemberclls:OtherCurrentLiabilities1Member2024-12-310001627281clls:CashAndCashEquivalentMemberifrs-full:Level1OfFairValueHierarchyMember2024-12-310001627281clls:IncomeLossMember2025-01-012025-06-300001627281ifrs-full:LaterThanFiveYearsMember2025-06-300001627281ifrs-full:BuildingsMember2023-12-310001627281ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberclls:OfficeAndLaboratoryEquipmentMember2024-06-300001627281ifrs-full:TopOfRangeMember2024-01-012024-06-300001627281clls:TrancheCWarrantsMemberclls:EuropeanInvestmentBankLoanMember2024-12-180001627281clls:NonCurrentLeaseDebtsMemberifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember2025-06-300001627281clls:NonCurrentFinancialAssetsMemberifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember2025-06-300001627281ifrs-full:LandAndBuildingsMemberifrs-full:GrossCarryingAmountMember2025-06-300001627281ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2023-12-310001627281ifrs-full:ConstructionInProgressMember2023-12-310001627281clls:OtherCurrentFinancialLiabilitiesMember2024-12-310001627281clls:CurrentFinancialAssetsMemberifrs-full:FinancialAssetsAtAmortisedCostCategoryMember2024-12-310001627281ifrs-full:RetainedEarningsMember2023-12-310001627281clls:TrancheCWarrantsMemberclls:ExpectedVolatilityPlusFivePercentMember2025-06-300001627281clls:FixturesFittingsAndOtherEquipmentMember2024-12-310001627281ifrs-full:BuildingsMember2024-01-012024-06-300001627281ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember2025-06-300001627281clls:BpifranceMember2024-12-310001627281clls:StockOption1Member2024-01-012024-12-310001627281clls:OtherCurrentLiabilities1Member2024-12-310001627281clls:TrancheBWarrantsMember2025-06-300001627281clls:NonCurrentFinancialAssetsMemberifrs-full:FinancialAssetsAtAmortisedCostCategoryMember2025-06-300001627281clls:TotalCurrentFinancialLiabilitiesAndCurrentLeaseDebtsMember2025-06-300001627281clls:OtherNonCurrentFinancialLiabilitiesMember2025-06-300001627281ifrs-full:GrossCarryingAmountMember2024-12-310001627281clls:EuropeanInvestmentBankWarrantsMember2024-12-310001627281clls:BPIRefundableAdvanceAgreementMember2023-03-082023-03-080001627281ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2025-06-300001627281clls:CashAndCashEquivalentMemberifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember2025-06-300001627281country:FR2025-04-012025-06-300001627281clls:ClinicalAndRdAgreementsMemberifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember2024-12-310001627281ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberclls:TechnicalEquipmentsMember2025-06-300001627281ifrs-full:TopOfRangeMemberclls:StockOption1Member2025-01-012025-06-300001627281ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberclls:OtherCurrentLiabilities1Member2025-06-300001627281ifrs-full:TopOfRangeMemberclls:StockOption1Member2024-01-012024-06-300001627281clls:IncomeLossMember2025-06-300001627281clls:CashAndCashEquivalentMemberifrs-full:Level2OfFairValueHierarchyMember2024-12-310001627281clls:CalyxtIncMember2017-09-300001627281clls:BPIRefundableAdvanceAgreementMember2023-03-080001627281clls:BPIRefundableAdvanceAgreementMemberclls:BpifranceMember2025-01-012025-06-300001627281clls:ClinicalAndRdAgreementsMemberifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember2025-06-300001627281clls:FixturesFittingsAndOtherEquipmentMemberifrs-full:GrossCarryingAmountMember2025-06-300001627281clls:StockOption1Member2025-06-300001627281ifrs-full:ConstructionInProgressMember2025-01-012025-06-300001627281clls:SellingGeneralAndAdministrativeExpenses1Member2024-01-012024-06-300001627281clls:ClinicalAndRdAgreementsMember2024-12-310001627281ifrs-full:Level3OfFairValueHierarchyMember2025-06-300001627281clls:BPIRefundableAdvanceAgreementMember2024-12-310001627281clls:CashAndCashEquivalentMemberifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember2024-12-3100016272812025-01-012025-06-300001627281ifrs-full:NotLaterThanOneYearMember2024-12-310001627281ifrs-full:TradeReceivablesMemberifrs-full:FinancialAssetsAtAmortisedCostCategoryMember2024-12-310001627281clls:ClinicalAndRdAgreementsMemberifrs-full:LaterThanFiveYearsMember2024-12-310001627281ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember2025-06-300001627281country:FR2024-04-012024-06-300001627281clls:ExecutiveEmployeesMemberclls:StockOption1Member2025-01-302025-01-300001627281ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2024-01-012024-06-300001627281clls:ClinicalAndRdAgreementsMemberifrs-full:LaterThanFiveYearsMember2025-06-300001627281ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberclls:CurrentLeaseDebtsMember2025-06-300001627281ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember2024-12-310001627281clls:Non-CurrentLeaseLiabilitiesMember2025-01-012025-06-300001627281ifrs-full:IssuedCapitalMemberifrs-full:OrdinarySharesMember2024-01-012024-06-3000016272812024-12-310001627281clls:EuropeanInvestmentBankLoanTrancheBMember2024-01-252024-01-250001627281ifrs-full:RetainedEarningsMember2024-06-300001627281clls:Non-CurrentPortionOfState-GuaranteedLoanMember2024-12-310001627281ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember2025-06-300001627281clls:ResearchAndDevelopmentExpensesMember2025-04-012025-06-300001627281clls:FixturesFittingsAndOtherEquipmentMember2025-01-012025-06-300001627281clls:NonCurrentDerivativeInstrumentsMemberifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember2024-12-310001627281clls:OfficeAndLaboratoryEquipmentMember2024-12-310001627281ifrs-full:ConstructionInProgressMember2024-06-300001627281clls:EuropeanInvestmentBankLoanTrancheAMember2023-04-172023-04-170001627281clls:ClinicalAndRdAgreementsMemberifrs-full:NotLaterThanOneYearMember2024-12-310001627281clls:BpifranceMemberclls:ResearchTaxCreditFinancingsMember2023-06-152023-06-150001627281clls:TotalNon-CurrentFinancialLiabilitiesAndNon-CurrentLeaseDebtsMember2025-01-012025-06-300001627281clls:AstraZenecaIrelandMemberclls:JointCollaborationAndResearchAgreementMember2025-01-012025-06-300001627281ifrs-full:ConstructionInProgressMember2024-01-012024-06-300001627281clls:StockOption1Member2024-01-012024-06-300001627281ifrs-full:LandAndBuildingsMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2024-06-300001627281clls:TrancheBWarrantsMemberclls:EuropeanInvestmentBankLoanMember2024-01-250001627281ifrs-full:TradeReceivablesMember2024-12-310001627281clls:OtherProvisionForChargesMember2025-01-012025-06-300001627281clls:ITLicensingAgreementMemberifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember2024-12-310001627281ifrs-full:LandAndBuildingsMember2025-06-300001627281clls:TrancheAWarrantsMember2023-04-172023-04-170001627281clls:CellectisIncMember2024-01-012024-06-300001627281clls:NonCurrentLeaseDebtsMemberifrs-full:Level3OfFairValueHierarchyMember2024-12-310001627281clls:SubsidiesReceivablesMemberifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember2024-12-310001627281clls:TrancheBWarrantsMember2024-01-250001627281clls:FixturesFittingsAndOtherEquipmentMember2023-12-310001627281clls:ITLicensingAgreementMemberifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember2025-06-300001627281clls:OfficeAndLaboratoryEquipmentMember2025-01-012025-06-300001627281ifrs-full:SharePremiumMember2023-12-310001627281clls:SubsidiesReceivablesMemberifrs-full:FinancialAssetsAtAmortisedCostCategoryMember2024-12-310001627281ifrs-full:AccumulatedImpairmentMember2025-06-300001627281clls:Non-CurrentPortionOfState-GuaranteedLoanMember2025-06-300001627281clls:StateGuaranteedLoanMemberifrs-full:TopOfRangeMember2025-06-300001627281clls:TrancheAWarrantsMember2023-04-170001627281clls:EuropeanInvestmentBankLoanMember2025-04-012025-06-300001627281ifrs-full:Level1OfFairValueHierarchyMember2024-12-3100016272812025-06-3000016272812024-01-012024-06-3000016272812024-06-300001627281clls:CurrentFinancialAssetsMemberifrs-full:Level1OfFairValueHierarchyMember2025-06-300001627281clls:CurrentFinancialLiabilitiesMemberifrs-full:Level2OfFairValueHierarchyMember2024-12-310001627281clls:ITLicensingAgreementMemberifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember2025-06-300001627281clls:OtherProvisionForChargesMember2024-12-310001627281clls:EuropeanInvestmentBankLoanMember2024-12-310001627281ifrs-full:IssuedCapitalMemberifrs-full:OrdinarySharesMember2023-12-310001627281clls:ResearchAndDevelopmentExpensesMember2025-01-012025-06-300001627281clls:BPIRefundableAdvanceAgreementMemberifrs-full:InterestRateMeasurementInputMember2023-06-190001627281clls:StateGuaranteedLoanMember2020-07-312020-07-3100016272812024-04-012024-06-300001627281ifrs-full:TradeReceivablesMemberifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember2025-06-300001627281ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember2025-06-300001627281clls:CashAndCashEquivalentMemberifrs-full:Level3OfFairValueHierarchyMember2024-12-310001627281ifrs-full:Level1OfFairValueHierarchyMemberclls:OtherCurrentLiabilities1Member2024-12-310001627281ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:ConstructionInProgressMember2025-06-300001627281clls:ITLicensingAgreementMemberifrs-full:NotLaterThanOneYearMember2025-06-300001627281clls:SubsidiesReceivablesMemberifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember2025-06-300001627281clls:SellingGeneralAndAdministrativeExpenses1Member2025-01-012025-06-300001627281ifrs-full:OrdinarySharesMember2024-06-3000016272812025-04-012025-06-300001627281clls:TrancheCWarrantsMember2024-12-180001627281clls:EuropeanInvestmentBankLoanMember2023-04-172023-04-170001627281clls:NonEmployeeWarrantsMember2025-01-012025-06-300001627281ifrs-full:IssuedCapitalMember2024-06-300001627281ifrs-full:BuildingsMember2024-06-300001627281ifrs-full:BottomOfRangeMember2025-01-012025-06-300001627281clls:NonCurrentLeaseDebtsMember2024-12-310001627281ifrs-full:Level2OfFairValueHierarchyMemberclls:CurrentFinancialAssetsMember2024-12-310001627281clls:TradePayablesMemberifrs-full:Level3OfFairValueHierarchyMember2024-12-310001627281clls:TechnicalEquipmentsMember2024-12-310001627281ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember2024-12-310001627281clls:NonEmployeeWarrantsMember2024-01-012024-06-300001627281clls:FreeSharesMember2024-12-310001627281clls:ClinicalAndRdAgreementsMember2025-06-300001627281clls:NonEmployeeWarrantsMember2023-01-012023-12-310001627281clls:EuropeanInvestmentBankLoanTrancheAMember2023-04-17iso4217:EURclls:Cellxbrli:pureiso4217:EURxbrli:sharesxbrli:sharesclls:Warrantsclls:Optionsiso4217:USDxbrli:sharesiso4217:USDclls:SegmentUnit

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K/A

Amendment No. 1 to Report on Form 6-K (Film No. 251180769)

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

Date of Report: October 14, 2025

Commission File Number: 001-36891

Cellectis S.A.

(Exact Name of registrant as specified in its charter)

8, rue de la Croix Jarry

75013 Paris, France

+33 1 81 69 16 00

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Explanatory Note

This report on Form 6-K/A (this “Amendment”) filed by Cellectis S.A. (the “Company”) amends the Company’s report on Form 6-K, which included the Company’s unaudited Condensed Consolidated Interim Financial Statements as of, and for the three- and six-month periods ended, June 30, 2025 (the “Report”), filed with the U.S. Securities and Exchange Commission on August 4, 2025, solely to provide the financial statements formatted in iXBRL (Inline eXtensible Business Reporting Language) in accordance with Rule 405 of Regulation S-T and paragraph C.(6)(a)(ii) of the General Instructions to Form 6-K. Exhibit 101 includes information in Inline eXtensible Business Reporting Language.

Other than as expressly set forth above, this Amendment does not, and does not purport to, amend, revise, update or restate the information presented in the Report or reflect any events that have occurred after the Report was originally filed.

Cellectis S.A.

The information included in this report on Form 6-K, including Exhibit 99.1, shall be deemed to be incorporated by reference in the registration statements of Cellectis S.A. on Form F-3 (Nos. 333-284302 and 333-288491) and Form S-8 (Nos. 333-204205, 333-214884, 333-222482, 333-227717, 333-258514, 333-267760, 333-273777 and 333-284301), to the extent not superseded by documents or reports subsequently filed.

EXHIBIT INDEX

Exhibit		Title
99.1		Cellectis S.A.’s interim report for the six-month period ended June 30, 2025.

101 The following materials from Cellectis S.A.’s Report on Form 6-K formatted in iXBRL (Inline eXtensible Business Reporting Language): (i) the Condensed Consolidated Statements of Financial Position (Unaudited), (ii) the Condensed Consolidated Statements of Operations (Unaudited), (iii) the Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited), (iv) the Condensed Consolidated Statements of Cash Flow (Unaudited), (v) the Condensed Consolidated Statements of Changes in Shareholders’ Equity (Unaudited), and (vi) the Notes to the Interim Consolidated Financial Statements.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	CELLECTIS S.A. (Registrant)
October 14, 2025	By:	/s/ André Choulika
		André Choulika
		Chief Executive Officer

FAQ

What did Cellectis (CLLS) file?

An amended Form 6-K/A adding iXBRL formatting to its previously filed interim financial statements.

Does this amendment change Cellectis’s results?

No. It does not amend, revise, update, or restate other information from the original report.

Which period do the financial statements cover?

The three- and six-month periods ended June 30, 2025.

What exhibits are included?

Exhibit 99.1 (interim report for six months ended June 30, 2025) and Exhibit 101 (iXBRL-formatted financial statements and notes).

Are these materials incorporated by reference into other registrations?

Yes. They are incorporated by reference into Cellectis’s Form F-3 (Nos. 333-284302, 333-288491) and Form S-8 filings listed.

What is the date of this report?

The Date of Report is October 14, 2025.